OrthoPediatrics (NASDAQ:KIDS) Shares Gap Up After Analyst Upgrade

OrthoPediatrics Corp. (NASDAQ:KIDS)’s stock price gapped up before the market opened on Tuesday after Needham & Company LLC raised their price target on the stock from $37.00 to $42.00. The stock had previously closed at $33.60, but opened at $35.00. Needham & Company LLC currently has a buy rating on the stock. OrthoPediatrics shares last traded at $35.44, with a volume of 160,769 shares traded.

Other analysts have also issued research reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $50.00 price target on shares of OrthoPediatrics in a report on Tuesday. Truist Financial downgraded OrthoPediatrics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $39.00 to $31.00 in a research report on Thursday, January 25th.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, CEO David R. Bailey sold 3,213 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total transaction of $88,646.67. Following the completion of the sale, the chief executive officer now owns 139,384 shares of the company’s stock, valued at approximately $3,845,604.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Fred Hite sold 3,195 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $27.59, for a total transaction of $88,150.05. Following the completion of the transaction, the chief financial officer now owns 94,072 shares in the company, valued at $2,595,446.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David R. Bailey sold 3,213 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $88,646.67. Following the completion of the sale, the chief executive officer now owns 139,384 shares in the company, valued at $3,845,604.56. The disclosure for this sale can be found here. Insiders have sold 17,253 shares of company stock worth $477,375 over the last ninety days. Company insiders own 31.80% of the company’s stock.

Institutional Trading of OrthoPediatrics

Large investors have recently made changes to their positions in the company. CWM LLC increased its holdings in shares of OrthoPediatrics by 16,283.3% in the fourth quarter. CWM LLC now owns 983 shares of the company’s stock worth $32,000 after acquiring an additional 977 shares in the last quarter. RiverPark Advisors LLC acquired a new stake in OrthoPediatrics during the 3rd quarter worth approximately $35,000. International Assets Investment Management LLC lifted its stake in OrthoPediatrics by 3,151.4% in the fourth quarter. International Assets Investment Management LLC now owns 1,203 shares of the company’s stock valued at $37,000 after buying an additional 1,166 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of OrthoPediatrics by 136.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,341 shares of the company’s stock valued at $107,000 after buying an additional 1,927 shares during the period. Finally, Quantbot Technologies LP increased its position in shares of OrthoPediatrics by 180.8% during the first quarter. Quantbot Technologies LP now owns 7,091 shares of the company’s stock worth $207,000 after acquiring an additional 4,566 shares in the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Trading Up 3.3 %

The firm has a market capitalization of $825.51 million, a price-to-earnings ratio of -37.72 and a beta of 1.16. The business’s fifty day moving average is $28.80 and its 200 day moving average is $29.04. The company has a quick ratio of 2.90, a current ratio of 5.44 and a debt-to-equity ratio of 0.03.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm had revenue of $37.61 million for the quarter, compared to the consensus estimate of $37.59 million. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. Equities analysts predict that OrthoPediatrics Corp. will post -1.34 earnings per share for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.